SHR-1826
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Zhongshan Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions
Advanced Solid TumorsHepatocellular CancerLung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)
Phase 1
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
RecruitingNCT06094556
Start: 2023-12-25End: 2027-07-31Target: 240Updated: 2025-04-13
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
RecruitingNCT06703177
Start: 2025-02-18End: 2027-07-01Target: 876Updated: 2025-12-03
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
RecruitingNCT06754930
Start: 2025-02-18End: 2027-12-31Target: 400Updated: 2025-04-17
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Not yet recruitingNCT07414953
Start: 2026-03-30End: 2028-11-30Target: 400Updated: 2026-02-17
Phase 2
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Not yet recruitingNCT06935175
Start: 2025-05-01End: 2028-05-31Target: 53Updated: 2025-04-20
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Not yet recruitingNCT07489716
Start: 2026-04-01End: 2028-12-01Target: 90Updated: 2026-03-24